ALK and non-small cell lung carcinoma: Park et al. has exhibited that the successive collection of TEP RNA adds predictive value in detecting EML4-ALK mutations, thereby enabling the prediction of favorable and unfavorable outcomes for ALK1 NSCLC patients who are undergoing treatment with alectinib or crizotinib (Park et al. 2019).